by WRAL TechWire May 14, 2021 .
MORRISVILLE – New funding in the form of $7 million in A Series B fROUND will accelerate the commercialization of the automated and individualized poultry vaccination systems, SAYS Morrisville-based Applied LifeSciences & Systems, or ALSS.
The round was co-led by Merck Animal Health and Mountain Group Partners, and included an investment from Oval Park Capital, a Raleigh-based early-stage investment firm, which was also an early investor.
According to the company, its high-speed imaging, feature recognition, artificial intelligence, robotics, and microfluidics proprietary technologies are integrated in a system developed to address a significant challenge for the commercial poultry industry: successful, efficient vaccinations.
/PRNewswire/ Applied LifeSciences & Systems (ALSS) announced today the initial close of a $7 million Series B equity financing. The financing was co-led by.
Alss Secures $7M in Series B Funding
Applied LifeSciences & Systems (ALSS), a Morrisville, NC-based biomedical systems company, held the initial close of a $7m Series B equity financing.
The round was co-led by Merck Animal Health and Mountain Group Partners with participation from Oval Park Capital.
The company intends to use the funds to accelerate the commercialization of its automated and individualized poultry vaccination systems.
Led by Ramin Karimpour, Founder and CEO, ALSS integrates its proprietary technologies in high-speed imaging, feature recognition, artificial intelligence, robotics and microfluidics in a system currently developed for the commercial poultry industry. This system can individually and accurately vaccinate up to 100,000 chicks per hour against diseases such as coccidiosis, infectious bronchitis and Newcastle disease.
UMass Amherst researchers achieve breakthrough in the fight against cancer
A team of researchers at the Center for Bioactive Delivery at the University of Massachusetts Amherst s Institute for Applied Life Sciences has engineered a nanoparticle that has the potential to revolutionize disease treatment, including for cancer. This new research, which appears today in
Angewandte Chemie, combines two different approaches to more precisely and effectively deliver treatment to the specific cells affected by cancer.
Two of the most promising new treatments involve delivery of cancer-fighting drugs via biologics or antibody-drug conjugates (ADCs). Each has its own advantages and limitations. Biologics, such as protein-based drugs, can directly substitute for a malfunctioning protein in cells. As a result, they have less serious side effects than those associated with traditional chemotherapy. But, because of their large size, they are unable to get into specific cells. ADCs, on the other
UMass Amherst team makes cancer ‘research breakthrough’
An exterior view of the Institute for Applied Life Sciences at University of Massachusetts Amherst is shown Oct. 21, 2016. GAZETTE FILE PHOTO
Published: 5/7/2021 5:35:06 PM
AMHERST Researchers at the University of Massachusetts Amherst have discovered a mechanism for more effectively delivering medical treatment to specific cells, representing a possible breakthrough in cancer treatment.
The research team at the university’s Center for Bioactive Delivery, based in the Institute for Applied Life Sciences, has managed to engineer a nanoparticle they say could revolutionize the way cancer-fighting drugs are delivered to specific cells. In a study published in the peer-reviewed journal of the German Chemical Society, Angewandte Chemie, the scientists explained that the nanoparticle combines two different approaches to delivering treatment to cells.